The HLTF Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal knockout cell population in which the HLTF gene has been targeted for disruption within the human A-549 cell line. This product offers a heterogeneous pool of edited cells, each carrying distinct HLTF mutations, thereby avoiding clonal selection artifacts and allowing for the assessment of ensemble gene function. The knockout model is designed for researchers seeking to investigate the consequences of HLTF loss in a lung adenocarcinoma background.
The A-549 cell line is historically derived from the lung adenocarcinoma of a 58-year-old male and serves as a well-characterized model of human alveolar basal epithelial cells. A-549 cells are widely utilized in cancer biology, drug metabolism, and toxicology studies due to their epithelial morphology, adherent growth, and retention of certain type II pneumocyte features. Their relevance to lung adenocarcinoma research makes them an appropriate host for exploring tumor suppressor gene function, particularly in the context of DNA damage responses that are critical for cancer development and therapy.
HLTF encodes a dual-function DNA helicase and E3 ubiquitin ligase that is recruited to stalled replication forks upon activation by ATM and ATR kinases. There, it interacts with PCNA and RAD18, and its ubiquitin ligase activity catalyzes K63-linked polyubiquitination of PCNA to promote fork reversal and homologous recombination repair, involving FANCD2 and RAD51. HLTF transcription is regulated by E2F1 and p53, and it forms complexes with SHPRH and UBE2N/UBC13. Thus, HLTF loss disrupts DNA repair and contributes to genomic instability.
Given that A-549 cells originate from lung adenocarcinoma, the HLTF knockout model is particularly relevant for investigating tumor-suppressive roles and DNA repair deficiencies in this cancer type. HLTF is frequently downregulated or mutated in lung and colorectal cancers, and its loss compromises the cellular response to replication-damaging agents such as hydroxyurea or camptothecin. Therefore, these polyclonal knockout cells serve as a valuable tool for studying how HLTF deficiency sensitizes cancer cells to chemotherapeutics and for dissecting the interplay between replication stress and transformation in alveolar epithelial cells.
The HLTF Knockout A-549 Polyclonal Cells are suitable for a range of functional studies, including Western blotting, RT-qPCR, and immunofluorescence for ??H2AX foci to assess DNA damage responses. They enable clonogenic survival assays following treatment with DNA-damaging agents, replication fork protection assays, and ubiquitination analysis to examine PCNA modifications. Co-immunoprecipitation can be used to study HLTF interactors, and cell cycle analysis provides insights into proliferation defects. These cells support research in cancer biology, DNA repair, tumor suppression, and drug discovery. For further information, please contact Ascent Research.
